BACKGROUND: Cutaneous @entity5 are frequent in organ transplant recipients. We retrospectively reviewed a large series of heart transplant recipients and report on the prevalence and risk factors for development of @entity1491 . METHODS: Between Dec. 4, 1985, and Dec. 27, 1996, 299 heart transplantations were performed at the Oregon Health Sciences University. Heart transplant recipients with more than 6 months survival or follow-up were investigated for @entity1491 (n = 248). RESULTS: Forty-one @entity1 (17%) were found to have 192 @entity1491 . @entity957 was the predominate @entity272 , constituting 172 (90%) of the lesions. The mean number of @entity272 per @entity1 was 4.7 +/- 0.81 (range 125). @entity1 with development of a @entity272 were 8 years older on average, with a male-to-female ratio of 19.5:1. The predominant @entity8492 were fair (59%) and blue (59%), respectively. Cumulative risk, based on actuarial survival analysis for development of a @entity1491 at 1 year, was 3% and increased to 21% and 35% at 5 and 10 years, respectively. In addition, cumulative risk increased in @entity1 who received treatment with OKT3. CONCLUSION: Cumulative risk of development of a @entity272 increased with time and use of OKT3. Additional @entity1 risk factors included older age, male sex, fair skin, and @entity735 .

XXXX in heart transplant recipients.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancies'] @entity957 :: ('MESH:D002294', 'Disease') :: ['Squamous cell carcinoma'] @entity735 :: ('MESH:D005124', 'Disease') :: ['blue eyes'] @entity8492 :: ('MESH:D012868', 'Disease') :: ['skin type and eye color'] @entity272 :: ('MESH:D012871', 'Disease') :: ['skin malignancies', 'skin malignancy'] @entity1491 :: ('MESH:D002280', 'Disease') :: ['cutaneous squamous and basal cell carcinoma', 'squamous and basal cell carcinoma', 'squamous or basal cell carcinoma', 'squamous or basal cell carcinomas']
@entity1491 :: (MESH:D002280,Disease) :: ['Squamous and basal cell carcinoma']
